Senores Pharmaceuticals delivered impressive June-quarter results with consolidated net profit rising 55.70% year-on-year to ₹30.72 crore and revenue increasing 38.30% to ₹180.21 crore compared to ₹130.30 crore in the previous year. According to the latest financial results reported by Business Standard, operating profit margin (OPM) expanded to 29.83% from 26.22% a year earlier, demonstrating the company's enhanced operational efficiency. The company's regulated markets business continued to lead growth during the quarter, with revenue from the segment rising 42% year-on-year. As per Business Standard, the strong financial performance demonstrates the company's ability to capitalize on its strategic focus on regulated markets and operational efficiency improvements.
The company nearly doubled its approved ANDA portfolio over the past year, increasing it from 30 approved ANDAs in June 2025 to 58 approvals by June 2026, of which 23 products have already been commercialised. As reported by Business Standard, Senores has adopted a balanced strategy of combining in-house product development with targeted acquisitions to strengthen its presence in regulated markets. The emerging markets business also maintained healthy momentum, recording around 30% year-on-year revenue growth during the quarter. According to Choice Institutional Equities research report dated July 27, 2026, the company now has ~35 approved ANDAs in the US and over 500 approved products across Emerging Markets, planned for launch in 18–20 months. This strategic expansion has positioned the company well for continued growth in both regulated and emerging markets segments.
The company highlighted the strategic importance of its recently added USFDA-approved manufacturing facility in Baroda, which is expected to improve scalability and support faster product launches in regulated markets. According to Business Standard, the facility is also expected to enhance operating leverage, strengthen margins and create additional opportunities in the contract development and manufacturing (CDMO) and contract manufacturing (CMO) businesses. Production has already been ramped up at the Apnar facility, with full-scale expansion expected over the next 12 to 18 months. As per Choice Institutional Equities, the successful scale-up of the Apnar acquisition, coupled with ongoing capacity expansion at the US facility, reinforces confidence in the company's long-term growth strategy.
Choice Institutional Equities has recommended a 'BUY' rating on Senores Pharma with a target price of ₹1,795, citing the company's strong product and market expansion prospects. According to the latest research report, the brokerage expects the company to sustain its growth trajectory, delivering a revenue CAGR of 35% in the next three years, in line with management's guidance. Choice Institutional Equities anticipates EBITDA margin to remain healthy at 28–29% in FY27E and FY28E, while the implied PEG ratio of 0.9x supports the constructive valuation outlook. The research firm has revised its FY27E/FY28E estimates upwards by 4.9%/10.3% respectively, valuing the stock at 35x FY28E EPS. Following the earnings announcement, shares of Senores Pharmaceuticals Ltd climbed to an intraday high of ₹1,443.70 before trimming gains, as reported by Business Standard.
